Poxel
POXEL | PA
Overview
Corporate Details
- ISIN(s):
- FR0012432516
- LEI:
- 9695003OIX0T7NX72N26
- Country:
- France
- Address:
- 259 AVENUE JEAN JAURES, 69007 LYON
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterium-modified thiazolidinedione (dTZD) platforms targeting chronic and rare metabolic diseases. Poxel’s first-in-class lead product, TWYMEEG® (Imeglimin), that targets mitochondrial dysfunction, has been approved for the treatment of type 2 diabetes in Japan.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 17:45 |
Delisting Announcement
Inside Information / Other news releases
|
English | 109.8 KB | |
| 2025-08-08 17:45 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 96.7 KB | |
| 2025-08-01 07:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 134.8 KB | |
| 2025-08-01 07:30 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 164.3 KB | |
| 2025-07-08 18:46 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 110.8 KB | |
| 2025-06-30 18:32 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 109.4 KB | |
| 2025-06-30 18:32 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 95.0 KB | |
| 2025-06-06 19:05 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 76.2 KB | |
| 2025-05-28 07:30 |
Earnings Release
Inside Information / Other news releases
|
English | 95.0 KB | |
| 2025-05-28 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 119.8 KB | |
| 2025-05-26 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 98.0 KB | |
| 2025-05-26 18:00 |
Environmental & Social Information
Informations privilégiées / Autres communiqués
|
French | 86.7 KB | |
| 2025-05-13 07:30 |
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
|
French | 153.8 KB | |
| 2025-05-13 07:30 |
Earnings Release
Inside Information / Information on annual revenues
|
English | 130.6 KB | |
| 2025-05-06 17:45 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 84.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-29 | N/A | Other | Buy | 80,000 | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Ascelia Pharma | Sweden | ACE | |
|
Atrys Health S.A. | Spain | ATRY | |
|
AUKETT SWANKE GROUP PLC | United Kingdom | AUK | |
|
Azorean - Aquatic Technologies S.A. | Portugal | MLAAT | |
|
Bachem Holding AG | Switzerland | BANB | |
|
Bavarian Nordic | Denmark | BAVA | |
|
BB Biotech AG | Switzerland | BION | |
|
BEEKS FINANCIAL CLOUD GROUP PLC | United Kingdom | BKS | |
|
BenevolentAI | United Kingdom | BAI | |
|
BerGenBio | Norway | BGBIO |